• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    DeepHealth Launches Reporting Pro, Bringing AI Automation to Radiology Reporting

    6/10/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care
    Get the next $RDNT alert in real time by email

    SOMERVILLE, Mass., June 10, 2026 (GLOBE NEWSWIRE) --  DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), today announced the launch of Reporting Pro, a next-generation AI-powered solution designed to transform the way radiologists generate clinical reports and findings for their referring physicians.

    Reporting Pro was introduced at RSNA 2025 and is now available for commercial deployment. Reporting Pro includes capabilities that bring speech recognition, AI-generated clinical findings, measurements, AI-generated impressions, quality assurance and structured reporting into one seamless workflow.

    "Radiology is entering a new era where AI supports the diagnostic journey from image analysis to reporting. Reporting Pro is a critical step forward, bringing intelligence into the reporting workflow so radiologists can focus on review and refinement, rather than manual documentation," said Madhu Jahagirdar, Business and Product Leader, Enterprise Imaging, DeepHealth.

    As imaging volumes continue to rise, radiology demand is expected to outpace workforce capacity. Radiologist shortage is projected to reach about 15% by 2029 in the United States,1 and approximately 40% by 2030 in certain European countries.2 Reporting remains one of the most time-intensive and cognitively demanding steps for radiologists, creating a crucial opportunity to help them work more efficiently and consistently.

    Reporting Pro automates high-volume reporting tasks with key capabilities including:

    • Clinical AI integration: Reporting Pro integrates clinical AI findings and measurements from FDA-cleared and CE-marked DeepHealth and third-party AI tools into the reporting workflow, enabling clinically relevant results to flow directly into structured report creation.



    • Generative AI-powered reporting: Reporting Pro uses generative AI to help organize findings and generate draft impressions. The platform adapts based on physician feedback to better support how findings are summarized and structured, helping accelerate reporting while maintaining a high level of clinical quality.

    • Fast migration, deployment and adoption: Reporting Pro integrates with existing workflows. The solution supports migration of existing templates and reporting preferences from legacy reporting systems, enabling radiologists to maintain familiar workflows while adopting a more intelligent, AI-native reporting experience.



    • Streamlined and automated reporting workflow: Reporting Pro connects speech recognition, clinical AI findings, measurements, AI-generated impressions, quality assurance and structured reporting capabilities into one unified experience. With integration of DeepHealth's native clinical AI solutions, radiologists can review AI-supported draft content, refine it as needed and finalize reports within a connected reporting environment without any manual data transfer.



    Reporting Pro is being deployed across RadNet at scale, providing real-world validation of its capability to support faster, consistent reporting across high-volume clinical environments. The first set of external customers for Reporting Pro have also been contracted, with deployments going live within the next quarter.

    "With Reporting Pro, a structured report is already waiting when I open a case with findings populated, measurements in place and a preliminary report drafted.  That significantly reduces reporting times, translating directly to faster turnaround times for patients and referring physicians who rely on receiving reports on a timely basis in order to make critical treatment decisions," said Dr. Jason Sinner, Radiologist and Medical Director, RadNet.

    Reporting Pro is designed to integrate with any existing picture archiving and communication system (PACS) and radiology information system (RIS). When deployed together with DeepHealth's Diagnostic Suite,3 the solutions deliver a seamless reporting experience, connecting image management, AI findings, workflow orchestration and reporting. This helps route, prioritize, review and report cases more efficiently.

    Reporting Pro is commercially available in the United States and the United Kingdom, with plans to release it in Australia, South Africa and select European markets by the end of the year. The platform is available across all imaging modalities, including X-ray, Ultrasound, CT, PET/CT and MRI.

    DeepHealth will demonstrate Reporting Pro alongside its enterprise informatics portfolio of solutions at the Society of Imaging Informatics in Medicine (SIIM) Annual Meeting 2026 at booth #105-107.

    About DeepHealth  

    DeepHealth is a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT) and serves as the umbrella brand for RadNet's Digital Health segment.  DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging.  DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in breast, chest, musculoskeletal, neuro, prostate and thyroid health.  At the heart of DeepHealth's portfolio is a cloud-native operating system – DeepHealth OS – that unifies data across the clinical and operational workflow.  Thousands of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable and more efficient disease detection, including in large-scale cancer screening programs.  DeepHealth's human-centered, intuitive technology aims to push the boundaries of what's possible in healthcare. Learn more at deephealth.com. 

    About RadNet, Inc. 

    RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue.  RadNet has a network of owned and/or operated outpatient imaging centers.  RadNet's imaging center markets include Arizona, California, Delaware, Florida, Idaho, Indiana, Maryland, New Jersey, New York, Texas and Virginia.  In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry globally.  Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members.  Learn more at radnet.com. 

    Forward Looking Statements

    This communication contains certain "forward-looking statements" within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "outlook," "plan," "potential," "possible," "predict," "project," "seek," "should," "target," "will" or "would," the negative of these words, and similar references to future periods. Examples of forward-looking statements include statements regarding our technology's ability to stage-shift disease through proactive, timely intervention and discussions regarding our product features. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet's control.

    Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations and assumptions regarding the future of RadNet's business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet's control. RadNet's actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. Neither RadNet, nor any of its directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet's business and the ability to realize the expected benefits of the technology. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the technology, and (2) the risk of legislative, regulatory, economic, competitive, and technological changes, and other risks and uncertainties described in the "Risk Factors," "Management's Discussion and Analysis," and other sections of our filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in RadNet's filings with the Securities and Exchange Commission (the "SEC"), including the risk factors discussed in RadNet's most recent Annual Report on Form 10-K, as updated by its Quarterly Reports on Form 10-Q and future filings with the SEC.

    Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

    DeepHealth Media Contact

    Andra Axente

    Director of Communications

    +31614440971

    andra.axente@deephealth.com

    RadNet Media Contacts 

    Jane Mazur 

    Senior Vice President, Corporate Communications 

    +1 585-355-5978 

    jane.mazur@radnet.com  



    Mark Stolper

    Executive Vice President and Chief Financial Officer

    +1 310-445-2800

    References

    1. Health Resources and Services Administration. "Workforce Projections." National Center for Health Workforce Analysis, n.d., data.hrsa.gov/topics/health-workforce/nchwa/workforce-projections. Accessed Sept 2025.
    2. Royal College of Radiologists Clinical Radiology Census 2024/25.
    3. Diagnostic Suite comprises multiple applications, including DeepHealth Viewer. DeepHealth Viewer is manufactured by eRAD, Inc. and distributed by DeepHealth, Inc. Any claims made about Diagnostic Suite may reference claims associated with its individual components.



    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/36e18576-8f41-44a5-9d1c-cf1c7309d34a



    Get the next $RDNT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RDNT

    DatePrice TargetRatingAnalyst
    1/9/2026$92.00Overweight
    KeyBanc Capital Markets
    6/13/2025$69.00Buy
    B. Riley Securities
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    9/6/2024$57.00 → $79.00Equal Weight → Overweight
    Barclays
    3/6/2024$48.00Equal Weight
    Barclays
    8/31/2023$40.00Buy
    Truist
    3/31/2023$30.00Market Outperform
    CJS Securities
    3/3/2023$30.00Mkt Perform → Outperform
    Raymond James
    More analyst ratings

    $RDNT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    KeyBanc Capital Markets initiated coverage on RadNet with a new price target

    KeyBanc Capital Markets initiated coverage of RadNet with a rating of Overweight and set a new price target of $92.00

    1/9/26 9:07:04 AM ET
    $RDNT
    Medical Specialities
    Health Care

    B. Riley Securities initiated coverage on RadNet with a new price target

    B. Riley Securities initiated coverage of RadNet with a rating of Buy and set a new price target of $69.00

    6/13/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet upgraded by Raymond James with a new price target

    Raymond James upgraded RadNet from Outperform to Strong Buy and set a new price target of $65.00 from $85.00 previously

    3/5/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RadNet Secures $250 Million Incremental Term Loan to Fund Strategic Growth Opportunities and Reduces the Interest Rates on its Credit Facility by 0.25%

    LOS ANGELES, June 10, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of outpatient imaging centers and a premier developer of radiology digital health solutions, today announced that it has entered into Incremental Amendment No. 3 (the "Third Amendment") to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the "Existing Credit Agreement" and, as amended by the Third Amendment, the "Credit Agreement"). Pursuant to the Third Amendment, certain term lenders under the Credit Agreement funded RadNet an incremental t

    6/10/26 4:05:00 PM ET
    $RDNT
    Medical Specialities
    Health Care

    DeepHealth Launches Reporting Pro, Bringing AI Automation to Radiology Reporting

    SOMERVILLE, Mass., June 10, 2026 (GLOBE NEWSWIRE) --  DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), today announced the launch of Reporting Pro, a next-generation AI-powered solution designed to transform the way radiologists generate clinical reports and findings for their referring physicians. Reporting Pro was introduced at RSNA 2025 and is now available for commercial deployment. Reporting Pro includes capabilities that bring speech recognition, AI-generated clinical findings, measurements, AI-generated impressions, quality assurance and structured reporting into one seamless workflow. "Radiology is ent

    6/10/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Announces a Proposed $200 Million Incremental Term Loan to Fund Strategic Growth Opportunities

    LOS ANGELES, June 03, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT) ("RadNet"), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of outpatient imaging centers and a premier developer of radiology digital health solutions, today announced that it seeks to secure an incremental term loan in the aggregate principal amount of $200 million (the "Proposed 2026 Incremental Term Loan") pursuant to a proposed amendment (the "Proposed Amendment") to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the "Existing Credit Agreement" and, the transaction, the "Loan Transaction"). If

    6/3/26 8:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    SEC Filings

    View All

    RadNet Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    6/10/26 5:23:08 PM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - RadNet, Inc. (0000790526) (Filer)

    6/3/26 9:08:18 PM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - RadNet, Inc. (0000790526) (Filer)

    6/3/26 8:07:02 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Swartz David L sold $145,449 worth of shares (2,699 units at $53.89), decreasing direct ownership by 2% to 177,013 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    6/22/26 4:15:18 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Pres & CEO, Digital Health Wesdorp Cornelis sold $276,022 worth of shares (4,750 units at $58.11), decreasing direct ownership by 6% to 69,075 units (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    6/18/26 6:03:03 PM ET
    $RDNT
    Medical Specialities
    Health Care

    President, CEO Berger Howard G gifted 90 shares (SEC Form 4)

    4 - RadNet, Inc. (0000790526) (Issuer)

    6/18/26 6:00:23 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Leadership Updates

    Live Leadership Updates

    View All

    The Oncology Institute Announces Addition of Board Member Mark Stolper

    CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute's board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ:RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncolog

    1/5/26 8:30:00 AM ET
    $RDNT
    $TOI
    Medical Specialities
    Health Care
    Medical/Nursing Services

    RadNet, Inc. Announces the Appointment of Kees Wesdorp as President and Chief Executive Officer of RadNet's Digital Health Division

    Former Chief Business Leader of Philips' multi-billion-dollar Precision Diagnosis division and member of Philips' Executive CommitteeEnd-to-end responsibility for Philip's CT, MR, dXR, Ultrasound and Diagnostic Informatics (radiology software) businessesProven track record of building and managing radiology software solutions, including significant experience with AI development and commercialization LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers and digital health solutions, announced today the appo

    9/12/24 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Financials

    Live finance-specific insights

    View All

    RadNet Reports Record First Quarter Financial Results and Revises Upwards 2026 Imaging Center Financial Guidance Ranges for Revenue, Adjusted EBITDA and Free Cash Flow

    Total Company Revenue increased 22.1% to $575.6 million in the first quarter of 2026 from $471.4 million in the first quarter of 2025Revenue from the Digital Health reportable segment increased 51.5% to $29.1 million in the first quarter of 2026 from $19.2 million in the first quarter of 2025; Annual Recurring Revenue(4) (ARR) increased from $49.8 million at March 31, 2025 to $96.9 million at March 31, 2026Total Company Adjusted EBITDA(1) was $63.3 million in the first quarter of 2026 as compared with $46.4 million in the first quarter of 2025, an increase of 36.3%; Digital Health reportable segment Adjusted EBITDA(1) decreased to $1.3 million in the first quarter of 2026 from $3.7 million i

    5/10/26 4:05:00 PM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet, Inc. Announces Date of its First Quarter 2026 Financial Results Conference Call

    LOS ANGELES, April 28, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services and digital health solutions, announced today that it will host a conference call to discuss its first quarter 2026 financial results on Monday, May 11, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-744-1280. International callers can dial 412-564-6465. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1761306&tp_key=ea5d61284c. An archived replay of the call will also be available

    4/28/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    RadNet, Inc. Reminds Investors of the Dedicated Conference Call and Presentation About the Recently Completed Acquisition of Gleamer SAS

    LOS ANGELES, March 04, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, reminds investors that on Thursday, March 5, 2026, investors are invited to join a dedicated conference call and presentation to hear more details about the recently completed acquisition of Gleamer SAS and RadNet's Digital Health strategy. On the call, investors will also have the opportunity to ask questions of executive management. Investor Call Details: The conference call will take place at 7:30 a.m. Pacific Time/10:30 am. Eastern Time/4:30 p.m. Centr

    3/4/26 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $RDNT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/12/24 4:51:53 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/4/24 1:22:38 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    10/24/24 6:36:21 PM ET
    $RDNT
    Medical Specialities
    Health Care